On Monday, Neogenomics Inc. (NASDAQ: NEO) was 7.64% up from the session before settling in for the closing price of $14.14. A 52-week range for NEO has been $11.03 – $21.22.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 17.35% over the last five years. When this article was written, the company’s average yearly earnings per share was at 96.81%. With a float of $126.20 million, this company’s outstanding shares have now reached $127.37 million.
The firm has a total of 2100 workers. Let’s measure their productivity.
Neogenomics Inc. (NEO) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Neogenomics Inc. stocks. The insider ownership of Neogenomics Inc. is 1.16%, while institutional ownership is 99.15%. The most recent insider transaction that took place on Mar 04 ’24, was worth 97,579. In this transaction Director of this company sold 6,112 shares at a rate of $15.97, taking the stock ownership to the 50,062 shares. Before that another transaction happened on Feb 15 ’24, when Company’s General Counsel sold 2,587 for $14.96, making the entire transaction worth $38,713. This insider now owns 34,866 shares in total.
Neogenomics Inc. (NEO) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 96.81% per share during the next fiscal year.
Neogenomics Inc. (NASDAQ: NEO) Trading Performance Indicators
You can see what Neogenomics Inc. (NEO) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.95. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.28.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.70, a number that is poised to hit -0.04 in the next quarter and is forecasted to reach 0.14 in one year’s time.
Technical Analysis of Neogenomics Inc. (NEO)
Analysing the last 5-days average volume posted by the [Neogenomics Inc., NEO], we can find that recorded value of 1.08 million was better than the volume posted last year of 0.91 million. As of the previous 9 days, the stock’s Stochastic %D was 61.77%. Additionally, its Average True Range was 0.70.
During the past 100 days, Neogenomics Inc.’s (NEO) raw stochastic average was set at 23.86%, which indicates a significant decrease from 69.37% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 49.74% in the past 14 days, which was lower than the 56.95% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $15.03, while its 200-day Moving Average is $15.40. Now, the first resistance to watch is $16.07. This is followed by the second major resistance level at $16.92. The third major resistance level sits at $17.80. If the price goes on to break the first support level at $14.35, it is likely to go to the next support level at $13.47. Now, if the price goes above the second support level, the third support stands at $12.62.
Neogenomics Inc. (NASDAQ: NEO) Key Stats
There are 127,666K outstanding shares of the company, which has a market capitalization of 1.94 billion. As of now, sales total 591,640 K while income totals -87,970 K. Its latest quarter income was 155,550 K while its last quarter net income were -14,330 K.
